Sci TransMed: New combination therapy or "cold" tumors that are expected to treat non-responsive conventional therapies.

July 13, 2020 // In a recent study published in the international journal Science Translational Medicine, scientists from the Sanford Burnham Prebys Institute for Medical Discovery and others have revealed the therapeutic potential of PRMT5 inhibitors in promoting the sensitivity of non-reactive melanoma to immunootherapy, and PRMT5 inhibitors are currently used in clinical trials of oncology, which provides strong evidence of the effectiveness of special drugs in immunotherapyDrZe'ev Ronai, aresearcher, points out that PRMT5 can help tumors evade immune system attacks by controlling two immune signaling pathways, inhibit the function of PRMT5 and enhance the presentation of antigens and activation of congenital immunity, which are necessary for effective immunocheckpoint therapy, and the results of this paper will lead to new treatment ideas for patients who are not effective with checkpoint inhibitor therapy in the short termPhoto Source: Askhematologist.com Immunotherapy can destroy tumors by controlling the body's immune system, which could revolutionise the treatment of certain cancers, and for some patients with advanced melanoma, it will extend the patient's survival from a few months to a few years, however, immunotherapy is only effective for about 40 percent of patients with advanced melanoma, and researchers are working to develop new treatments to make it more effective for more types of cancerresearchers, who call immunotherapy-inactive tumors "cold" tumors, are looking for ways to make them respond or become "hot" to thetherapy, and ways to help achieve this goal could be a major breakthrough in the field, the researchers used a mouse model of melanoma to study and found that combining PRMT5 inhibitors with anti-PD-1 therapy, a commonly used immunocheckpoint therapy, could convert unresponsive "cold" tumors into "hot" tumors, and found that mice that normally could not respond to PD-1 therapy would have a longer survival time and a smaller tumor in their body, possibly because of the increased effect of the immune system in miceThe development of immunocheckpoint inhibitors is a major advance in the treatment of advanced melanoma, with more than half of patients now surviving for five years or more, but a large proportion of patients who are resistant to the treatment, and a mechanism-based solution to current problems may be a late-stage study by researchers who have begun clinical trials to test whether PRMT5 inhibitors are effective in treating patients who do not respond to current immunotherapy, said Jedd Wolchok, M.D.,, the researchers identified two cell signaling pathways that can be suppressed by PRMT5 that promote tumors to escape detection by the host's immune system, one of which is mainly responsible for antigen delivery, and the other that controls cytokine production and congenital immunity, which also helps determine the extent to which tumors escape the host's immune system, which promotes the re-emergence of tumors that escape detection by the immune system and become sensitive to immune attacksresearchers say that prMT5's controlled immune signaling pathways are also directly related to the survival of melanoma patients, suggesting that patients with different reactions to PRMT5 inhibitors should be stratified depending on the expression of these pathwaycomponentsconcluded that the pathways we have found may help explain the mechanism by which different types of tumors produce/do not respond to immunocheckpoint therapy, and that the results may also have some clinical relevance to tumor patients other than melanomas whose immunootherapy has failedOriginal source of: Hyungsoo Kim, Heejung Kim, Yongmei Feng, et alPRMT5 control of cGAS/STING and NLRC5 cells sphinse scys scys sby s bouts to antitumor i, Science Translational Medicine 08 Jul 2020: Vol12, 551, eaaz5683